Brief: TCR2 Therapeutics Gets FDA Orphan Drug Designation For Cholangiocarcinoma Treatment
02/09/2021 14:22
Sept 2 (Reuters) - TCR2 Therapeutics Inc TCRR.O :
* TCR² THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR
GAVO-CEL FOR THE TREATMENT OF CHOLANGIOCARCINOMA
Source text for Eikon: ID:nGNX4fHZ3p
Further company coverage: TCRR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TCR2 Therapeutics
See all newsBrief: TCR2 Therapeutics Entered Into An Assignment Of Lease Agreement With Astrazeneca
TCR2 Therapeutics falls on bigger-than-expected Q1 loss
Brief: Tcr² Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update
TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
TCR2 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview